Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an...
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates PR Newswire CRANFORD, N.J., July...
New York, NY, Jan. 10, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (Nasdaq: TENKU, TENK, TENKR) (the...
Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain...
New York, NY, Oct. 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (NASDAQ: TENKU) today...
New York, NY, July 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (NASDAQ: TENKU) today...
0001851484 false Q1 --12-31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 &nb...
OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number:3235-0145 Expires:Febuary 28...
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the...
New York, NY, Dec. 06, 2022 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (Nasdaq: TENKU), a...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관